01477.HK
Ocumension Therapeutics
HKSE · Healthcare · Biotechnology · CN
HKD 4.79
+3.90%Oct 28, 2026, 01:29 UTC
China's Ocumension Therapeutics approved Ocumension Therapeutics' fluocinolone intravitreal implant for domestic production in mainland China.
Source:Oct 20, 2026, 00:36 UTC
Ocumension Therapeutics announced preliminary top-line results from the month-36 primary analysis of its global Phase III trial of OT-101, meeting the prespecified primary endpoint criterion for the China region.
Source:Sep 10, 2026, 23:51 UTC
Ocumension Therapeutics announced that China's National Medical Products Administration Center for Drug Evaluation accepted its new drug application for OT-301 (NCX 470, bimatoprost) for lowering intraocular pressure in open-angle glaucoma or ocular hypertension.
Source:Sep 3, 2026, 01:37 UTC
Ocumension Therapeutics announced that the Phase III clinical trial of OT-211 (TRYPTYR acotiamide eye drops) in China has completed enrollment of 398 patients.
Source:Aug 31, 2026, 13:56 UTC
Ocumension Therapeutics announced that the first patient has been enrolled in the Phase III clinical trial of OT-202 for dry eye disease in China.
Source:Jun 18, 2026, 05:49 UTC
Nicox's exclusive licensee Ocumension received positive pre-submission regulatory feedback from the Chinese Center for Drug Evaluation for NCX 470, supporting a planned NDA submission in China.